“There is an apprehension that sales may be impacted with slower recovery in rural areas than expected,” said Nirvi Ashar, fundamental research analyst at Religare Broking. The company is scheduled to announce its first-quarter results on August 4.
UBS sells shares worth Rs 480 crore in Concord Biotech, IIFL Securities, 2 more stocks via block deals
UBS sold holdings in Concord Biotech, Five Star Business Finance, IIFL Securities, and Marksans Pharma through block deals, totaling Rs 480 crore. The largest sale